Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (51-60 of 274) with videos related to

Pageof 28
Sort By:
Kidney Cancer (Clifton, Va.)|October 19, 2018
Kidney Cancer Incidence in California: End of the Trend?Cyllene R Morris, Primo N Lara, Arti Parikh-Patel, et al.
Expert Opinion on Pharmacotherapy|April 2, 2003
Docetaxel in non-small cell lung cancer: a reviewAngela M Davies, Primo N Lara, Philip C Mack, et al.
Nature Reviews. Nephrology|May 9, 2017
Metabolic reprogramming in clear cell renal cell carcinomaHiromi I Wettersten, Omran Abu Aboud, Primo N Lara, et al.
Urology|October 1, 2013
Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer RegistryAshok Pai, Ann Brunson, Monica Brown, et al.
Cancer Treatment Reviews|June 6, 2003
Current strategies in the management of hormone refractory prostate cancerCynthia L Martel, Paul H Gumerlock, Frederick J Meyers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Incorporating bortezomib into the treatment of lung cancerAngela M Davies, Primo N Lara, Philip C Mack, et al.
Anti-Cancer Drugs|May 24, 2013
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumorsThomas J Semrad, Courtney Eddings, Mrinal P Dutia, et al.
Current Opinion in Oncology|December 2, 2010
Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancerSacha I Rothschild, Oliver Gautschi, Primo N Lara, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 4, 2010
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]David R Gandara, Philip C Mack, Tianhong Li, et al.
Current Drug Targets|October 21, 2009
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancerTianhong Li, Primo N Lara, Philip C Mack, et al.
Pageof 28

Showing results (51-60 of 274) with videos related to

Sort By:
Pageof 28
Kidney Cancer (Clifton, Va.)|October 19, 2018
Kidney Cancer Incidence in California: End of the Trend?Cyllene R Morris, Primo N Lara, Arti Parikh-Patel, et al.
Expert Opinion on Pharmacotherapy|April 2, 2003
Docetaxel in non-small cell lung cancer: a reviewAngela M Davies, Primo N Lara, Philip C Mack, et al.
Nature Reviews. Nephrology|May 9, 2017
Metabolic reprogramming in clear cell renal cell carcinomaHiromi I Wettersten, Omran Abu Aboud, Primo N Lara, et al.
Urology|October 1, 2013
Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer RegistryAshok Pai, Ann Brunson, Monica Brown, et al.
Cancer Treatment Reviews|June 6, 2003
Current strategies in the management of hormone refractory prostate cancerCynthia L Martel, Paul H Gumerlock, Frederick J Meyers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Incorporating bortezomib into the treatment of lung cancerAngela M Davies, Primo N Lara, Philip C Mack, et al.
Anti-Cancer Drugs|May 24, 2013
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumorsThomas J Semrad, Courtney Eddings, Mrinal P Dutia, et al.
Current Opinion in Oncology|December 2, 2010
Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancerSacha I Rothschild, Oliver Gautschi, Primo N Lara, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 4, 2010
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]David R Gandara, Philip C Mack, Tianhong Li, et al.
Current Drug Targets|October 21, 2009
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancerTianhong Li, Primo N Lara, Philip C Mack, et al.
Pageof 28